BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.63 --0%
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +32.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
- Academy Sports surges on earnings beat and raised guidance
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
